furosemide has been researched along with n-vinyl-2-pyrrolidinone in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (30.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Doherty, C; York, P | 2 |
| Gärtner, K; Ulbrich, M; Vogel, G | 1 |
| Kulagin, IB | 1 |
| Bernabei, MT; Coppi, G; Fontana, F; Iannuccelli, V; Leo, E | 1 |
| Bolger, MB; De Zordi, N; Del Rio Castillo, AE; Grassi, M; Kikic, I; Moneghini, M; Solinas, D | 1 |
| Donoso, MD; Haskell, RJ; Schartman, RR | 1 |
| Fahmy, SA; Galeel, OW; Rasool, BK | 1 |
| Müllertz, A; Nielsen, LH; Rades, T | 1 |
| Geraniou, E; Siamidi, A; Vlachou, M | 1 |
10 other study(ies) available for furosemide and n-vinyl-2-pyrrolidinone
| Article | Year |
|---|---|
The in-vitro pH-dissolution dependence and in-vivo bioavailability of frusemide-PVP solid dispersions.
Topics: Adult; Biological Availability; Capsules; Chemistry, Pharmaceutical; Crystallization; Furosemide; Humans; Hydrogen-Ion Concentration; Male; Povidone; Solubility; Spectrophotometry, Ultraviolet; X-Ray Diffraction | 1989 |
[Exchange of plasma albumin (131-I-albumin) between extra- and intra-vascular space of the kidney, the lymphatic flow of macromolecules (polyvinylpyrrolidone) in the kidney under conditions of normal and furosemide-inhibited tubular reabsorption. Studies
Topics: Absorption; Animals; Depression, Chemical; Diffusion; Extracellular Space; Furosemide; Glomerular Filtration Rate; Kidney; Kidney Tubules; Lymph; Macromolecular Substances; Povidone; Rabbits; Serum Albumin; Serum Albumin, Radio-Iodinated | 1969 |
[A case of acute renal failure after rifampicin use].
Topics: Acute Kidney Injury; Anabolic Agents; Anti-Inflammatory Agents, Non-Steroidal; Female; Flavonoids; Furosemide; Humans; Kaempferols; Middle Aged; Nandrolone; Nandrolone Decanoate; Povidone; Rifampin | 1994 |
PVP solid dispersions for the controlled release of furosemide from a floating multiple-unit system.
Topics: Chemistry, Pharmaceutical; Delayed-Action Preparations; Diuretics; Furosemide; Povidone; Solubility | 2000 |
Evidence for solid- and liquid-state interactions in a furosemide-polyvinylpyrrolidone solid dispersion.
Topics: Furosemide; Magnetic Resonance Spectroscopy; Povidone; Spectrophotometry, Infrared; Spectroscopy, Fourier Transform Infrared | 1987 |
Applications of supercritical fluids to enhance the dissolution behaviors of Furosemide by generation of microparticles and solid dispersions.
Topics: Biological Availability; Carbon Dioxide; Crystallization; Diuretics; Drug Stability; Furosemide; Gastric Juice; Hydrogen-Ion Concentration; Microspheres; Models, Theoretical; Particle Size; Povidone; Solubility; Solvents; Technology, Pharmaceutical; Time Factors | 2012 |
Surfactant choice and the physical stability of nanosuspensions as a function of pH.
Topics: Dioctyl Sulfosuccinic Acid; Drug Compounding; Drug Stability; Furosemide; Hydrogen-Ion Concentration; Itraconazole; Ketoconazole; Nanoparticles; Piroxicam; Povidone; Surface-Active Agents; Suspensions | 2012 |
Impact of chitosan as a disintegrant on the bioavailability of furosemide tablets: in vitro evaluation and in vivo simulation of novel formulations.
Topics: Administration, Oral; Biological Availability; Cellulose; Chemistry, Pharmaceutical; Chitosan; Computer Simulation; Excipients; Furosemide; Hardness; Hardness Tests; Models, Biological; Povidone; Powders; Pressure; Sodium Potassium Chloride Symporter Inhibitors; Solubility; Starch; Tablets; Technology, Pharmaceutical | 2012 |
Stabilisation of amorphous furosemide increases the oral drug bioavailability in rats.
Topics: Administration, Oral; Animals; Biological Availability; Chemistry, Pharmaceutical; Crystallization; Drug Compounding; Drug Stability; Furosemide; Glass; Hydrogen-Ion Concentration; Male; Pharmaceutical Solutions; Povidone; Rats; Rats, Sprague-Dawley; Solubility; Transition Temperature | 2015 |
Modified release of furosemide from Eudragits® and poly(ethylene oxide)-based matrices and dry-coated tablets.
Topics: Chemistry, Pharmaceutical; Delayed-Action Preparations; Diuretics; Drug Compounding; Drug Liberation; Excipients; Furosemide; Hydrogen-Ion Concentration; Lactose; Molecular Weight; Polyethylene Glycols; Polymethacrylic Acids; Povidone; Tablets | 2020 |